Only in Titles

Search results for: Recombinant Human CRABP2 Proteins

paperclip

Error loading info... Pleas try again later.
paperclip

#21605859   2011/05/24 To Up

Impaired expansion of trophoblast spheroids cocultured with endometrial cells overexpressing cellular retinoic acid-binding protein 2.

We previously showed that the cellular retinoic acid-binding protein 2 (CRABP2) gene was up-regulated during the implantation window period in the endometrium of patients with unexplained recurrent spontaneous abortion. Here, we report that trophoblast spheroids cocultured with a human endometrial cell line stably overexpressing CRABP2 are defective in expansion and exhibit apoptosis, suggesting that the altered expression level of endometrial CRABP2 is involved in abnormal endometrium-trophoblast interaction, which leads to implantation failure.
Jiae Lee, Jeong Su Oh, Chunghee Cho

1751 related Products with: Impaired expansion of trophoblast spheroids cocultured with endometrial cells overexpressing cellular retinoic acid-binding protein 2.

96tests1 mg100 1 G 100ul200 1x96 well plate100.00 ug1mg1mg100 µl10

Related Pathways

paperclip

#18006143   2007/10/06 To Up

LIF removal increases CRABPI and CRABPII transcripts in embryonic stem cells cultured in retinol or 4-oxoretinol.

Murine embryonic stem (ES) cells cultured without leukemia inhibitory factor (LIF) or with retinoids differentiate and concomitantly metabolize retinol (vitamin A) to 4-oxoretinol. Our objective was to examine the effects of retinol or 4-oxoretinol on cellular retinoic acid binding protein (CRABP) I and II mRNA levels and retinol metabolism. ES cells were cultured with or without LIF, and with various doses of all-trans-retinol, all-trans-4-oxoretinol, or all-trans-retinoic acid (RA). In ES cells treated with retinol or 4-oxoretinol in the absence of LIF the CRABP-I (Crabp1, NM_013496; GI:7304974) and CRABP-II (Crabp2, NM_007759; GI:33469074) mRNA levels at 72h were 66+/-4 and 413+/-6 fold higher, respectively, than the levels in control ES cells cultured without retinoids and in the presence of LIF. The increase in CRABPI mRNA occurred through an increase in CRABPI gene transcription. CRABPI protein was also increased by >50-fold in cells treated with retinol in the absence of LIF. However [(3)H]4-oxoretinol does not bind to murine CRABPI or CRABPII. CYP26A1 mRNA levels and [(3)H]4-oxoretinol production from [(3)H]retinol increased in cells cultured without LIF and with exogenous retinoids. The enormous increases in CRABPI and II transcripts ( approximately 60 and 400-fold, respectively) in the absence of LIF may regulate aspects of the ES cell differentiation program in response to retinol.
Michelle A Lane, Juliana Xu, Elana W Wilen, Renia Sylvester, Fadila Derguini, Lorraine J Gudas

1134 related Products with: LIF removal increases CRABPI and CRABPII transcripts in embryonic stem cells cultured in retinol or 4-oxoretinol.

10 ug1 mg96 assays-

Related Pathways

paperclip

#17667529   // To Up

Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.

To evaluate the feasibility, efficacy, and biologic effects of weekly liposome-encapsulated all-trans retinoic acid (ATRA-IV) plus interferon alpha2b (IFN) in patients with advanced renal cell carcinoma (RCC). Twenty-six patients with metastatic RCC were treated on a phase 1/2 trial with weekly ATRA-IV and IFN SQ daily 5 d/wk. Twelve patients received ATRA-IV at three dose levels (60, 75, and 90 mg/m2) according to phase 1 methodology, and 14 additional patients received 90 mg/m2. Response was assessed according to an intention-to-treat analysis. Serum retinoic acid (RA) concentrations were assayed and peripheral blood mononuclear cell mRNA expression of RA and IFN-inducible genes (RARalpha, RARbeta2, IRF1, CRABP2, and TRAIL) were examined. No dose limiting toxicities occurred at 60 mg/m2; grade 3 leukopenia affected 1/6 patients at 75 mg/m2, whereas 3 patients received 90 mg/m2 without a dose limiting toxicities. Fourteen additional patients received 90 mg/m2 ATRA-IV without grade 3/4 toxicity. Five of 26 (19%) patients achieved a major response, with a median duration of 14 months (range 9 to 23); 9 additional patients (41%) demonstrated stable disease or minor response lasting > or =4 months. No significant differences in serum (RA) after ATRA infusion were detected between weeks 1 and 8 of treatment. Peripheral blood mononuclear cell mRNA expression did not correlate with clinical response. The addition of weekly ATRA-IV to IFN therapy is feasible and well tolerated, resulting in sustainable increased serum (RA). This regimen demonstrates antitumor activity in metastatic RCC, and suggests ATRA-IV augments IFN therapy.
Stephen A Boorjian, Matthew I Milowsky, Jodi Kaplan, Martin Albert, Marta Vallee Cobham, Deirdre M Coll, Nigel P Mongan, Gary Shelton, Daniel Petrylak, Lorraine J Gudas, David M Nanus

2581 related Products with: Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.

1 G

Related Pathways

paperclip

#11053266   // To Up

Novel locus for autosomal recessive cone-rod dystrophy CORD8 mapping to chromosome 1q12-Q24.

To map the disease locus of a two-generation, consanguineous Pakistani family with autosomal recessive cone-rod dystrophy (arCRD). All affected individuals had night blindness, deterioration of central vision, photophobia, epiphora in bright light, and problems with color distinction. Fundoscopy revealed marked macular degeneration and attenuation of retinal vessels. Mild pigmentary changes were present in the periphery.
S Khaliq, A Hameed, M Ismail, K Anwar, B P Leroy, S Q Mehdi, A M Payne, S S Bhattacharya

1706 related Products with: Novel locus for autosomal recessive cone-rod dystrophy CORD8 mapping to chromosome 1q12-Q24.

100 µg1 moduleOne 96-Well Strip Micropl200 100 mg1 kit 1 G1 mg1 module100 TESTS25 mg300 units

Related Pathways